Calcium sensitivity enhancers

IDrugs

Volumn 3, Issue 10, 2000, Pages 1199-1205

  Haikala, Heimo ^a   Pollesello, Piero ^a  

^a Orion Pharma   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013302144     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix, CH, Bommer, WJ, Elkayam, U, Kukin, ML: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. New Engl J Med (1991) 325(21):1468-75.
2. The xamoterol in severe heart failure study group: Xamoterol in severe heart failure. Lancet (1990) 336:1-6.
3. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne, B: Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol (1994) 46(3):191-6.
4. Sasayama S: Inotropic agents in the treatment of heart failure: despair or hope? Cardiovas Drugs Ther (1997) 10(6):703-9.
5. Gwathmey JK, Morgan JP: The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret. Br J Pharmacol (1985) 85(1):97-108.
6. Holubarsch C: New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology (1997) 88(Suppl 2):12-20.
7. 2+ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ Res (1982) 51(3):290-4.
8. Rüegg JC: [Calcium regulation of muscle contraction: the molecular regulation mechanisms of contracility]. Naturwissenschaften (1987) 74(12):579-84.
9. Teramura S, Yamakado T: Calcium sensitizers in chronic heart failure: inotropic interventions-reservation to preservation. Cardiologia (1998) 43(4):375-85.
10. Papp, JG: Positive inotropy by calcium sensitization - An evolving approach for the treatment of end-stage heart failure. Am J Cardiol (1999) 83(12B):1(I)-3(I).
11. 2+ activation of skinned human myocardium. Eur J Pharmacol (1989) 165:305-308.
12. Strauss JD, Bletz C, Rüegg JC: The calcium sensitizer EMD 53998 antagonizes phosphate-induced increases in energy cost of isometric tension in cardiac skinned fibers. Eur J Pharmacol (1994) 252(2):219-224.
13. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Lindén I-B: Troponin C mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol (1995) 25(5):794-801.
14. Holroyde M, Robertson SP, Johnson JD, Solaro RJ, Potter JD: The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem (1980) 255(24):11688-11693.
15. Putkey JA, Sweeney HL, Campbell ST: Site-directed mutation of the trigger calcium-binding sites in cardiac troponin C. J Biol Chem (1989) 264(21):12370-12378.
16. Filatov VL, Katrukha AG, Bulargina TV, Gusev NB: Troponin: structure, properties, and mechanism of functioning. Biochemistry (1999) 64:969-85.
17. Tao T, Gong BJ, Grabarek Z, Gergely J: Conformational changes induced in troponin I by interaction with troponin T and actin/tropomyosin. Biochim Biophys Acta (1999) 1450(3):423-33.
18. Perry SV: Troponin I: inhibitor or facilitator. Mol Cell Biochem (1999) 190:9-32.
19. Strynadka NC, Cherney M, Sielecki AR, Li MX, Smillie LB, James MN: Structural details of a calcium-induced molecular switch: X-ray crystallographic analysis of the calcium-saturated N-terminal domain of troponin C at 1.75 Å resolution. J Mol Biol (1997) 273(1):238-55.
20. 2+ binding to the regulatory domains of cardiac and E41A skeletal muscle troponin C reveal the importance of site I to energetics of the induced structural changes. Biochemistry (1997) 36(41):12519-25.
21. 2+-binding to troponin C. Adv Exp Med Biol (1998) 453:157-67.
22. 2+ regulatory sites of skeletal and cardiac troponin C in skinned muscle fibres. J Muscle Res Cell Motility (1997) 18(5):599-609.
23. Kitada Y, Narimatsu A, Matsumura N, Endo M: Contractile proteins: possible targets for the cardiotonic action of MCI-154, a novel cardiotonic agent? Eur J Pharmacol (1987) 134(2):229-231.
24. 2+ sensitivity of contractile proteins. Circulation (1986) 73:III78-III84.
25. Honerjager P, Heiss A, Schafer-Korting M, Schonsteiner G, Reiter M: UD-CG 115-a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn-Schmiedebergs Arch Pharmacol (1984) 325(3):259-69.
26. Böhm M, Morano I, Pieske B, Rüegg JC, Wankerl M, Zimmermann R, Erdmann, E: Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res (1991) 68(3):689-701.
27. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta, EG: Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res (1993) 73:981-990.
28. 2+sensitizing agent, and (+)-5-[1-(3,4-dimethoxy benzoyl)-1,2,3,4-tetrahydroquinolin-6-yl]-6-methyl-3,6-dihydro-2H-1,3,4- thiadiazin-2-one on skinned fibres and isolated ventricular strips. Arzneimittelforschung (1996) 46:586-93.
29. Holubarsch C, Ludemann J, Wiessner S, Ruf T, Schulte-Baukloh H, Schmidt-Schweda S, Pieske B, Posival H, Just H: Shortening versus isometric contractions in isolated human failing and non-failing left ventricular myocardium: dependency of external work and force on muscle length, heart rate and inotropic stimulation. Cardiovasc Res (1998) 37(1):46-57.
30. Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, Schmitz W, Scholz H, Wenzlaff H: Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium. J Pharmacol Exp Ther (1996) 277(3):1572-8.
31. 2+-sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe and proton nuclear magnetic resonance study. J Biol Chem (1994) 269(46):28584-28590.
32. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén I-B: Cardiac troponin C as a target protein for a novel positive inotropic drug, levosimendan. J Mol Cell Cardiol (1995) 27(9):1859-1866.
33. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation (1993) 98:2141-7.
34. 2+ sensitivity of reconstituted thin filament. A study using a novel in vitro motility assay technique. Circ Res (1995) 76(4):626-33.
35. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea-pig heart. Circ Res (1995) 77:107-113.
36. 2+: comparison with sulmazole and pimobendan. J Pharmacol Exp Ther (1991) 257(2):812-9.
37. Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G: The novel cardiotonic agent EMD 53998 is a potent "calcium sensitizer". J Cardiovasc Pharmacol (1991) 18(1):17-27.
38. i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol (1997) 339(1):97-100.
39. 2+ sensitizing effect of (+)-enantiomer EMD 57033 on diastolic function but not on systolic function in rabbit ventricular cardiomyocytes. Jpn J Pharmacol (1999) 80(1):55-65.
40. Abe Y, Sekioka K, Ishisu R, Onishi K, Ueda Y, Nakano T: Restoration of ischemic contractile failure of indo-1-loaded guinea pig heart by a calcium sensitizer, MCI-154. J Pharmacol Exp Ther (1996) 279(2):47-55.
41. 2+ sensitizer with no chronotropic activity in mammalian cardiac muscle. J Pharmacol Exp Ther (1998) 287:214-22.
42. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol (1998) 30(6):1115-28.
43. Kristof E, Szigeti G, Papp Z, Bodi A, Facso A, Kovacs L, Papp, JG, Kranias, EG, Edes, I: Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts: Effects on cAMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci (1998) 853:316-319.
44. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H: Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol (1995) 26(Suppl 1):S45-51.
45. Penefsky ZJ: The determination of contractility in the heart. Comp Biochem Physiol (1994) 109A:1-22.
46. Haikala H, Levijoki J, Lindén I-B: Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol (1995) 27(10):2155-2165.
47. Kleerekoper Q, Putkey JA: Drug binding to cardiac troponin C. J Biol Chem (1999) 274(34):23932-9.
48. Pan B-S, Johnson R: Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C. J Biol Chem (1996) 271:817-823.
49. Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpeläinen, I, Haikala, H: Further evidence for the cardiac troponin C mediated calcium sensitization by Levosimendan: structure-response and binding analysis with analogs of Levosimendan. J Mol Cell Cardiol (2000) 32(3):479-491.
50. Pethig R, Kuhn M, Payne R, Adler E, Chen T-H, Jaffe LF: On the dissociation constants of BAPTA-type calcium buffers. Cell Calcium (1989) 10(7):491-498.
51. 2+ binding by MCI-154, a novel cardiotonic agent. J Pharmacol Exp Ther (1989) 250(1):272-277.
52. Solaro RJ, Fujino K, Sperelakis N: The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol (1989) 14:S7-S12.
53. Moiseyev VS, Andrejevs N, Lehtonen LA, Lie KI, Ruda MY, Kobalava J, Pöder, P, Nieminen, MS. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarct. J Card Fail (1999) 5(3 Suppl 1):43
54. Follath F, Cleland JGF, Just H, Papp J, Scholz H, Peuhkurinen K, Harjola, VP, Mitrovich, V, Abdulla, M., Lehtonen, L: Efficacy and safety of intravenous levosimendan in severe low-output heart failure. A randomized, double-blind comparison to dobutamine (The LIDO-study). J Card Fail (1999) 5(3 Suppl 1):57.